ProKidney (PROK) Competitors $1.55 -0.05 (-3.13%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PROK vs. DNAB, DNAD, VPCB, FLYA, LGST, GMTX, HRMY, ARVN, GLPG, and RXRXShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Social Capital Suvretta Holdings Corp. II (DNAB), Social Capital Suvretta Holdings Corp. IV (DNAD), VPC Impact Acquisition Holdings II (VPCB), SOAR Technology Acquisition (FLYA), Semper Paratus Acquisition (LGST), Gemini Therapeutics (GMTX), Harmony Biosciences (HRMY), Arvinas (ARVN), Galapagos (GLPG), and Recursion Pharmaceuticals (RXRX). ProKidney vs. Social Capital Suvretta Holdings Corp. II Social Capital Suvretta Holdings Corp. IV VPC Impact Acquisition Holdings II SOAR Technology Acquisition Semper Paratus Acquisition Gemini Therapeutics Harmony Biosciences Arvinas Galapagos Recursion Pharmaceuticals Social Capital Suvretta Holdings Corp. II (NASDAQ:DNAB) and ProKidney (NASDAQ:PROK) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk. Do analysts rate DNAB or PROK? ProKidney has a consensus target price of $4.50, suggesting a potential upside of 190.32%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Social Capital Suvretta Holdings Corp. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Social Capital Suvretta Holdings Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the MarketBeat Community believe in DNAB or PROK? ProKidney received 8 more outperform votes than Social Capital Suvretta Holdings Corp. II when rated by MarketBeat users. CompanyUnderperformOutperformSocial Capital Suvretta Holdings Corp. IIN/AN/AProKidneyOutperform Votes857.14% Underperform Votes642.86% Is DNAB or PROK more profitable? ProKidney's return on equity of 0.00% beat Social Capital Suvretta Holdings Corp. II's return on equity.Company Net Margins Return on Equity Return on Assets Social Capital Suvretta Holdings Corp. IIN/A -73.34% 2.13% ProKidney N/A N/A -8.80% Does the media favor DNAB or PROK? In the previous week, Social Capital Suvretta Holdings Corp. II's average media sentiment score of 0.00 equaled ProKidney'saverage media sentiment score. Company Overall Sentiment Social Capital Suvretta Holdings Corp. II Neutral ProKidney Neutral Do insiders & institutionals have more ownership in DNAB or PROK? 76.6% of Social Capital Suvretta Holdings Corp. II shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, DNAB or PROK? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSocial Capital Suvretta Holdings Corp. IIN/AN/A$2.74MN/AN/AProKidneyN/AN/A-$35.47M-$0.59-2.63 Which has more risk and volatility, DNAB or PROK? Social Capital Suvretta Holdings Corp. II has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. SummaryProKidney beats Social Capital Suvretta Holdings Corp. II on 6 of the 9 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$448.99M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-2.6312.18115.5615.18Price / SalesN/A332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book-0.324.024.665.02Net Income-$35.47M-$42.25M$119.06M$225.46M7 Day Performance-11.43%8.06%0.80%0.37%1 Month Performance-5.78%8.71%5.65%3.57%1 Year Performance-14.84%32.10%36.76%29.44% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney1.4877 of 5 stars$1.55-3.1%$4.50+190.3%-6.9%$448.99MN/A-2.633Gap UpDNABSocial Capital Suvretta Holdings Corp. IIN/A$10.35+0.1%N/A+0.0%$330.06MN/A0.004DNADSocial Capital Suvretta Holdings Corp. IVN/A$10.35+0.1%N/A+0.0%$330.06MN/A0.004VPCBVPC Impact Acquisition Holdings IIN/A$10.28flatN/A+0.0%$328.55MN/A0.007FLYASOAR Technology AcquisitionN/A$10.41-0.4%N/A+0.0%$319.24MN/A0.002,021High Trading VolumeLGSTSemper Paratus AcquisitionN/A$4.51flatN/A-58.5%$71.35MN/A0.002,021Gap UpGMTXGemini TherapeuticsN/A$44.82-1.7%N/A+2.9%$1.94BN/A-44.8230HRMYHarmony Biosciences4.9032 of 5 stars$32.13-4.9%$47.00+46.3%+34.9%$1.93B$582.02M15.23200Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓Analyst RevisionNews CoverageHigh Trading VolumeARVNArvinas2.1178 of 5 stars$26.43-4.4%$56.92+115.4%+68.3%$1.90B$78.50M-5.66445Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGLPGGalapagos0.5862 of 5 stars$26.44-7.5%$31.00+17.2%-19.3%$1.88B$259.40M0.001,123Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeRXRXRecursion Pharmaceuticals2.9187 of 5 stars$6.32-5.4%$9.40+48.7%+25.7%$1.88B$44.58M-3.90400Upcoming Earnings Related Companies and Tools Related Companies DNAB Alternatives DNAD Alternatives VPCB Alternatives FLYA Alternatives LGST Alternatives GMTX Alternatives HRMY Alternatives ARVN Alternatives GLPG Alternatives RXRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROK) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
